Quarterly report pursuant to Section 13 or 15(d)

Segments (Details)

v2.4.0.8
Segments (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2014
Jun. 30, 2013
Dec. 31, 2013
Segment Reporting Information [Line Items]          
Product revenues $ 21,392 $ 18,618 $ 41,219 $ 34,145  
Revenue from services 2,153 3,188 4,123 6,280  
Revenue from transfer of intellectual property 0 2,015 476 14,772  
Operating (loss) income (34,885) (17,983) (65,160) (24,756)  
Depreciation and amortization 4,027 3,451 7,591 6,880  
Total revenues 23,545 23,821 45,818 55,197  
Assets 1,327,082 [1]   1,327,082 [1]   1,391,516 [1]
Goodwill 226,001 [1]   226,001 [1]   226,373 [1]
United States [Member]
         
Segment Reporting Information [Line Items]          
Total revenues 2,153 5,203 4,599 21,052  
Chile [Member]
         
Segment Reporting Information [Line Items]          
Total revenues 7,852 8,482 15,136 16,223  
Spain [Member]
         
Segment Reporting Information [Line Items]          
Total revenues 5,666 5,153 11,815 9,477  
Israel [Member]
         
Segment Reporting Information [Line Items]          
Total revenues 6,307 3,995 10,853 6,567  
Mexico [Member]
         
Segment Reporting Information [Line Items]          
Total revenues 1,546 988 3,377 1,878  
Uruguay [Member]
         
Segment Reporting Information [Line Items]          
Total revenues 21 0 38 0  
Corporate, Non-Segment [Member]
         
Segment Reporting Information [Line Items]          
Product revenues              
Revenue from services 60 80 120 120  
Revenue from transfer of intellectual property 0 0 0 0  
Operating (loss) income (7,038) (5,762) (13,174) (10,787)  
Depreciation and amortization 24 45 48 90  
Assets 156,993   156,993   209,539
Goodwill 0   0   0
Segment Reconciling Items [Member]
         
Segment Reporting Information [Line Items]          
Operating (loss) income (674) (943) (1,163) (1,540)  
Pharmaceutical | Operating Segments [Member]
         
Segment Reporting Information [Line Items]          
Product revenues 21,392 18,618 41,219 34,145  
Revenue from services 0 0 0 0  
Revenue from transfer of intellectual property 0 1,300 285 13,800  
Operating (loss) income (20,368) (4,528) (36,941) 3,955  
Depreciation and amortization 2,287 1,702 4,135 3,397  
Assets 1,059,635   1,059,635   1,065,033
Goodwill 175,036   175,036   175,408
Diagnostics | Operating Segments [Member]
         
Segment Reporting Information [Line Items]          
Product revenues              
Revenue from services 2,093 3,108 4,003 6,160  
Revenue from transfer of intellectual property 0 715 191 972  
Operating (loss) income (6,805) (6,750) (13,882) (16,384)  
Depreciation and amortization 1,716 1,704 3,408 3,393  
Assets 110,454   110,454   116,944
Goodwill $ 50,965   $ 50,965   $ 50,965
[1] As of June 30, 2014 and December 31, 2013, total assets include $7.7 million and $6.7 million, respectively, and total liabilities include $13.5 million and $10.4 million, respectively, related to SciVac Ltd (“SciVac”), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.